All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.

The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Multiple Myeloma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2020-04-07T18:18:25.000Z

MOR202 for patients with R/R multiple myeloma — results from a phase I–IIa trial

Apr 7, 2020
Share:

Bookmark this article

Anti-CD38 therapies, such as daratumumab (dara), have improved clinical outcomes in patients with multiple myeloma (MM). Unlike other currently exploited agents, the novel IgG1λanti-CD38 antibody MOR202 does not induce complement-dependent cytotoxicity (CDC), which has been associated with undesirable infusion-related reactions (IRRs). Alternative approaches to reduce the rate of IRRs include administering the drug as a split infusion, a schedule that was recently approved for daratumumab by the United States Food & Drug Administration (FDA).

MOR202, also known as TJ202, has been granted investigational new drug (IND) clearance by the National Medical Products Administration (NMPA) of China and is also being investigated in late-stage European trials for the treatment of patients with relapsed or refractory (R/R) MM (RRMM).

A first-in-human, multicenter, open-label, phase I-IIa trial (NCT01421186) in patients with RRMM is ongoing in Europe. The aim of the study is to characterize the safety, pharmacokinetic profile, and clinical activity of MOR202 both as a monotherapy and in combination with dexamethasone (dex) alone or dex plus an immunomodulatory drug (iMiD®). At the 23rd Congress of the European Hematology Association (EHA) 2018, Marc S. Raab presented results of MOR202 in combination with dexamethasone (dex), pomalidomide (pom) plus dex, and lenalidomide (len) plus dex.

Raab and colleagues have since published results, based on the primary completion analysis, in The Lancet Hematology; we hereby present a summary.1

Study design

  • Primary endpoints:
    • Maximum tolerated dose (MTD) of MOR202 as a monotherapy or in combination with dex ± an iMiD®
    • Recommended MOR202 dosing regimen
    • Adverse events (AEs)
  • Secondary endpoints (with sufficient data to be reported here) were overall response rate (ORR), proportion of patients with stable disease, duration of response (DoR), time to progression, and progression-free survival (PFS)
  • Data collection cut-off: December 31, 2017

Patient eligibility

  • Adult patients with RRMM (N = 91), were enrolled from nine hospitals in Germany and one in Austria. Definitions for RRMM varied by treatment subgroup:
    • MOR202 monotherapy or MOR202 + dex: ≥ 2 prior therapies including an IMiD and a proteasome inhibitor (PI)
    • MOR202 + pom + dex: ≥ 2 prior therapies including lenalidomide and a PI, with disease progression within 60 days of most recent therapy, and non-refractory/intolerant to pom
    • MOR202 + len + dex: ≥ 1 prior therapy
  • Patients had a Karnofsky performance status of ≥ 60%, adequate organ function, documented progression to most recent anti-myeloma therapy, and measurable disease defined as ≥ 1 of
    • serum monoclonal protein ≥ 0.5 g/100 mL and/or
    • urine monoclonal protein ≥ 200 mg per 24-hour period
    • bone marrow clonal plasma cell population
    • abnormal FLC ratio
  • Patients with primary refractory MM and those that had previously received an allogenic stem cell transplant (allo-SCT) and/or prior anti-CD38 therapy were excluded

Treatment

Eligible patients were assigned to a dose escalation (18; n = 67) or confirmation (n = 24) cohort and received treatment with intravenous (IV) MOR202 in 28-day cycles as per the dosing schedules illustrated in Table 1.

Table 1. MOR202 treatment regimens for dose escalation and confirmation cohort studies1

dex, dexamethasone; len, lenalidomide; pom, pomalidomide

*MOR202 was administered on Days 1 and 15. In Cycle 1, an additional loading dose was given on Day 4

MOR202 was administered on Days 1, 8, 15, and 22. In Cycle 1, an additional loading dose was given on Day 4

Dex (40 mg [≥ 75 years] or 20 mg [< 75 years]) was administered on Days 1, 8, 15, and 22 and on Day 4 of Cycle 1

§Pomalidomide (4 mg) or lenalidomide (25 mg) were administered orally once daily on Days 1–21 of the cycle

Regimen

Patients enrolled, n

Cohort number

MOR202 dose, mg/kg

Treated patients, n

Patients remaining on treatment, n

MOR202 bi-weekly*

31

1

2

3

4

5

6

7

8

0.01

0.04

0.15

0.50

1.50

4

8

16

4

4

3

3

3

3

3

8

0

MOR202

weekly

4

6

4

4

0

MOR202 +

dex

18

6

7

8

Confirmatory

4

8

16

16

3

4

4

7

0

MOR202 +dex +

pom§

21

7

8

Confirmatory

 

8

16

16

 

5

8

8

 

10

MOR202§ + dex +

len

17

7

8

Confirmatory

8

16

16

5

3

9

 

6

Results

Patient characteristics

  • At the time of enrollment, the majority (> 80%) of patients had received
    • autologous SCT (auto-SCT)
    • ≥ 2 lines of anti-MM treatment
  • Baseline patient characteristics are shown in Table 2

Table 2. Patient characteristics by treatment regimen1

auto-SCT, autologous stem cell transplant; dex, dexamethasone; ISS, International Stating System; IQR, interquartile range; KPS, Karnofsky performance status; len, lenalidomide; pom, pomalidomide; TEAE, treatment-emergent adverse event

Characteristic

MOR202 biweekly (n = 31)

MOR202 weekly (n = 4)

MOR202 + dex
(n = 18)

MOR202 + dex + pom (n = 21)

MOR202 + dex + len (n = 17)

Sex, % male

 

61

100

56

62

71

Median age, years (IQR)

≥ 65 years, %

71.0 (64.0–74.0)

 

26

68.5 (55.5–72.0)

25

67.0 (56.0–72.0)

39

65.0 (58.0–77.0)

 

48

66.0 (57.0–75.0)

47

High-risk cytogenetic status, %

26

50

28

38

35

Previous auto-SCT, %

81

100

83

81

88

Median number of previous treatment lines (IQR)

3.0 (2.0–4.0)

4.5 (2.5–8.5)

3.0 (2.0–4.0)

3.0 (2.0–3.0)

2.0 (1.0–2.0)

ISS Stage III

16

50

22

24

35

KPS 60–70%, %

13

0

6

14

12

 Safety

  • Treatment-emergent AEs (TEAEs) were observed in 100% of patients
    • The most common Grade ≥ 3 TEAEs are shown in Table 3
  • MOR202-related serious AEs were predominantly IRRs (10%) and pneumonia (4%)
  • Infusion-related reactions were observed in
    • 40% of patients receiving MOR202 monotherapy
    • 7% of patients receiving MOR202 as a combination treatment
  • MOR202 MTD was not reached in any cohort
  • No DLTs were observed at doses up to 8 mg/kg, but four DLTs were reported at 16 mg/kg
    • The main reason for discontinuation was disease progression in all cohorts, followed by AEs
    • Withdrawal due to MOR202-related, or suspected MOR202-related, TEAEs occurred in three patients in the MOR202 monotherapy cohorts and in two patients in the MOR202 combination cohorts
  • Five treatment-emergent deaths were observed, none of which were associated with MOR202
    • One death due to cardiovascular disorder in the MOR202 + dex + pom group was attributed to treatment with pom

Table 3. Grade ≥ 3 TEAEs reported by ≥ 10% of patients, by treatment regimen1

dex, dexamethasone; len, lenalidomide; pom, pomalidomide; TEAE, treatment-emergent adverse event

Grade ≥ 3 TEAE, %

MOR202 biweekly (n = 31)

MOR202 weekly (n = 4)

MOR202 + dex (n = 18)

MOR202 + dex + pom (n = 21)

MOR202 + dex + len (n = 17)

Any

 

52

100

83

95

100

Blood and lymphatic

Leukopenia               

Neutropenia

Lymphopenia

Anemia

Thrombocytopenia

 

6

0

16

6

3

 

75

50

50

0

25

 

11

22

39

17

17

 

57

71

52

14

24

 

47

53

 59

18

18

Diarrhea

0

0

0

10

6

Pneumonia

0

0

6

24

6

 

Respiratory tract infection

0

0

0

14

0

Hypophosphatemia

0

0

0

5

12

Plasma cell myeloma

6

25

6

0

0

Hypertension

10

0

11

19

12

Pericarditis

0

25

0

0

0

Supraventricular tachycardia

0

25

0

0

0

Cataract operation

0

25

0

0

0

Withdrawal due to TEAEs, %

13

50

6

14

18

Efficacy

  • Patient responses to MOR202 dosing schedules are illustrated in Table 4
  • Upon analysis of the results from this study, the suggested MOR202 treatment regimen for the treatment of adult patients with RRMM is
    • IV infusion of MOR202 for 30 minutes at doses up to 16 mg/kg + dex (40 mg) ± len (25 mg) or pom (4 mg)

Table 4. Patient responses to different MOR202 regimens1

CI, confidence interval; CR, complete response; Dex, dexamethasone; DoR, duration of response; len, lenalidomide; NA, not applicable; NE, not evaluable; NR, not reached; ORR, overall response rate; PD, partial disease; PFS, progression-free survival; pom, pomalidomide; PR, partial response; sCR, stringent complete response; SD, stable disease; TEAE, treatment-emergent adverse event; VGPR, very good partial response

Patient response

MOR202 biweekly
(n = 31)

MOR202 weekly
(n = 4)

MOR202 + dex
(n = 18)

MOR202 + dex + pom
(n = 21)

MOR202 + dex + len
(n = 17)

ORR, % (95% CI)

0 (0.0–11.2)

0 (0.0–60.2)

28 (9.7–53.5)

48 (25.7–70.2)

65 (38.3–85.8)

Best overall response, %

sCR

CR

VGPR

PR

Minimal

SD

PD

NE

 

0

0

0

0

0

19

74

6

 

0

0

0

0

0

75

25

0

 

0

0

11

17

11

39

22

0

 

5

5

14

24

19

10

10

14

 

6

6

12

41

6

6

6

18

Median DoR, months (95% CI)

NA

NA

16.7 (1.9–24.9)

16.6 (12.1–NR)

NR (4.2–NR)

Median time to progression, months (95% CI)

1.1 (1.0–1.4)

2.1 (0.7–9.9)

8.4 (1.4–11.1)

17.5 (4.1–NR)

NR (5.1–NR)

Median PFS, months (95% CI)

1.1 (1.0–1.4)

2.1 (0.7–9.9)

8.4 (1.4–11.1)

17.5 (3.0–NR)

NR (5.1–NR)

Conclusion

Results from this study suggest that MOR202 is safe and tolerable in heavily pre-treated patients with RRMM. Dex successfully reduced the frequency of infusion-related AEs compared to MOR202 alone, and a recommended treatment regimen for use in future trials was identified. Promising clinical activity and disease control were apparent in patients treated with MOR202 in combination with both dex alone and dex with pom or len.

Due to the stringent inclusion criteria for this study, there was some patient selection bias. Additionally, patients involved in clinical trials investigating alternative anti-CD38 therapies have generally received a greater number of previous lines of therapy than those enrolled in this study. These limitations should be considered with regard to real-world practice.

Future directions

  • Two confirmatory clinical trials are underway further investigating the efficacy of MOR202:
    • NCT03860038: single-arm phase II study investigating the combination of MOR202 with dex in patients with RRMM who have received ≥ 2 prior lines of treatment
    • NCT03952091: randomized phase III study investigating MOR202 in combination with dex plus len vs dex plus len in patients with RRMM who received ≥ 1 prior line of treatment
  1. Raab MS, Engelhardt M, Blank A, et al. MOR202, a novel anti-CD38 monoclonal antibody, in patients with relapsed or refractory multiple myeloma: a first-in-human, multicentre, phase 1-2a trial. Lancet Haematol.2020;S2352-3026(19)30249-2. DOI: 1016/S2352-3026(19)30249-2

Newsletter

Subscribe to get the best content related to multiple myeloma delivered to your inbox